Literature DB >> 27479018

Fulminant Liver Failure in a Child With β-Thalassemia on Deferasirox: A Case Report.

Archie Ramaswami1, Danya J Rosen, Jaime Chu, Birte Wistinghausen, Ronen Arnon.   

Abstract

Deferesirox (DFX), an oral chelating agent, is used to treat chronic iron overload in several hematological diseases such as β-thalassemia, sickle cell disease, and myelodysplastic anemia. DFX is generally well tolerated with the exception of gastrointestinal disturbances and rash, although cases of renal toxicity, as well as acute and chronic liver failure, have been reported in adults and children. Here we describe a 3-year-old girl with β-thalassemia undergoing treatment with DFX who presented with acute liver failure and Fanconi's syndrome. It is important for pediatric gastroenterologists, hepatologists, and hematologists to be aware that the commonly used drug DFX can lead to acute liver failure in children, and liver function should be monitored closely in all patients taking DFX.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27479018     DOI: 10.1097/MPH.0000000000000654

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  7 in total

1.  Significant Hyperbilirubinemia and Acute Hepatocellular Jaundice in a Pediatric Patient Receiving Deferasirox: A Case Report.

Authors:  Elizabeth A Feldman; Christopher D Miller; Sarabeth Wojnowicz; Robert Seabury
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jan-Feb

2.  Measurement of the liver iron concentration in transfusional iron overload by MRI R2* and by high-transition-temperature superconducting magnetic susceptometry.

Authors:  Sujit Sheth; Christopher J Allen; David E Farrell; John H Tripp; Ramin Jafari; Yi Wang; Gary M Brittenham
Journal:  Clin Imaging       Date:  2019-01-31       Impact factor: 1.605

Review 3.  The Cross-Link between Ferroptosis and Kidney Diseases.

Authors:  Jingyu Wang; Yi Liu; Yaqing Wang; Li Sun
Journal:  Oxid Med Cell Longev       Date:  2021-05-03       Impact factor: 6.543

4.  Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male.

Authors:  Jacqueline Fraser; Rowena Brook; Tony He; Diana Lewis
Journal:  BMJ Case Rep       Date:  2020-07-09

5.  The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability.

Authors:  Esther M Gottwald; Claus D Schuh; Patrick Drücker; Dominik Haenni; Adam Pearson; Susan Ghazi; Milica Bugarski; Marcello Polesel; Michael Duss; Ehud M Landau; Andres Kaech; Urs Ziegler; Anne K M Lundby; Carsten Lundby; Petra S Dittrich; Andrew M Hall
Journal:  Sci Rep       Date:  2020-01-31       Impact factor: 4.379

Review 6.  The Impact of Iron Chelators on the Biology of Cancer Stem Cells.

Authors:  Julia Szymonik; Kamila Wala; Tomasz Górnicki; Jolanta Saczko; Bartosz Pencakowski; Julita Kulbacka
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

Review 7.  Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review.

Authors:  Martin Scoglio; Maria Domenica Cappellini; Emanuela D'Angelo; Mario G Bianchetti; Sebastiano A G Lava; Carlo Agostoni; Gregorio P Milani
Journal:  Children (Basel)       Date:  2021-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.